Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 37 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.
Yaeger R, McKean MA, Haq R, Beck JT, Taylor MH, Cohen JE, Bowles DW, Gadgeel SM, Mihalcioiu C, Papadopoulos KP, Diamond EL, Sturtz KB, Feng G, Drescher SK, Reddy MB, Sengupta B, Maity AK, Brown SA, Singh A, [...] Rothenberg SM
Cancer Discov, 14(9):1599-1611, 01 Sep 2024
Cited by: 0 articles | PMID: 38691346 | PMCID: PMC11372368
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
Drilon A, Sharma MR, Johnson ML, Yap TA, Gadgeel S, Nepert D, Feng G, Reddy MB, Harney AS, Elsayed M, Cook AW, Wong CE, Hinklin RJ, Jiang Y, Brown EN, Neitzel NA, Laird ER, Wu WI, Singh A, [...] Rothenberg SM
Cancer Discov, 13(8):1789-1801, 01 Aug 2023
Cited by: 20 articles | PMID: 37269335 | PMCID: PMC10401072
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
Johnson M, Dudek AZ, Sukari A, Call J, Kunk PR, Lewis K, Gainor JF, Sarantopoulos J, Lee P, Golden A, Harney A, Rothenberg SM, Zhang Y, Goldman JW
Clin Cancer Res, 28(12):2517-2526, 01 Jun 2022
Cited by: 20 articles | PMID: 35302585 | PMCID: PMC9359741
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers LA, Cascone T, Behrang A, Meric-Bernstam F, Mooers BHM, Rothenberg SM, Ebata K, Wu J
Ann Oncol, 32(6):817-819, 20 Feb 2021
Cited by: 24 articles | PMID: 33617938 | PMCID: PMC8119360
Add to export list Free full text in Europe PMC
Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion-Positive Breast Cancer.
Watanabe S, Takeda M, Otani T, Yoshida T, Sakai K, Olek E, Rothenberg SM, Kherani J, French PP, Nishio K, Ito A, Nakagawa K
JCO Precis Oncol, 5:PO.20.00282, 11 Jan 2021
Cited by: 7 articles | PMID: 34036231 | PMCID: PMC8140803
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, [...] Cabanillas ME
N Engl J Med, 383(9):825-835, 01 Aug 2020
Cited by: 276 articles | PMID: 32846061 | PMCID: PMC10777663
Add to export list Free full text in Europe PMC
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
Kander EM, Shah MH, Zhou Y, Goyal A, Palmer JD, Owen DH, Shilo K, Patel G, Raval RR, Gonzalez J, Nguyen M, Olek E, Kherani J, Rothenberg SM, Konda B
Clin Lung Cancer, 22(3):e442-e445, 18 Jun 2020
Cited by: 3 articles | PMID: 32660930
Add to export list
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY, Johnson ML, Clifford SE, Somwar R, Kherani JF, Son J, Bertram AA, Davare MA, Gladstone E, Ivanova EV, Henry DN, Kelley EM, Lin M, Milan MSD, Nair BC, Olek EA, Scanlon JE, Vojnic M, Ebata K, [...] Oxnard GR
Clin Cancer Res, 27(1):34-42, 20 Oct 2020
Cited by: 55 articles | PMID: 33082208 | PMCID: PMC8009613
Add to export list Free full text in Europe PMC
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, [...] Subbiah V
N Engl J Med, 383(9):813-824, 01 Aug 2020
Cited by: 322 articles | PMID: 32846060 | PMCID: PMC7506467
Add to export list Free full text in Europe PMC
Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations.
Ortiz MV, Gerdemann U, Raju SG, Henry D, Smith S, Rothenberg SM, Cox MC, Proust S, Bender JG, Frazier AL, Anderson P, Pappo AS
JCO Precis Oncol, 4:PO.19.00401, 14 Apr 2020
Cited by: 20 articles | PMID: 32923911 | PMCID: PMC7450975
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma.
Dias-Santagata D, Lennerz JK, Sadow PM, Frazier RP, Govinda Raju S, Henry D, Chung T, Kherani J, Rothenberg SM, Wirth LJ
Thyroid, 30(9):1384-1389, 19 May 2020
Cited by: 18 articles | PMID: 32292131 | PMCID: PMC7482117
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, [...] Rothenberg SM
J Thorac Oncol, 15(4):541-549, 24 Jan 2020
Cited by: 113 articles | PMID: 31988000 | PMCID: PMC7430178
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma.
Hillier K, Hughes A, Shamberger RC, Shusterman S, Perez-Atayde AR, Wassner AJ, Iafrate AJ, Dubuc A, Janeway KA, Rothenberg SM, Cox MC, Randolph GW, Wirth LJ, Tsai H, Church A, DuBois SG
Thyroid, 29(11):1704-1707, 01 Nov 2019
Cited by: 11 articles | PMID: 31650892
Add to export list
Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases.
Guo R, Schreyer M, Chang JC, Rothenberg SM, Henry D, Cotzia P, Kris MG, Rekhtman N, Young RJ, Hyman DM, Drilon A
JCO Precis Oncol, 3, 03 Jun 2019
Cited by: 30 articles | PMID: 31485557 | PMCID: PMC6724540
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer.
Wirth LJ, Kohno T, Udagawa H, Matsumoto S, Ishii G, Ebata K, Tuch BB, Zhu EY, Nguyen M, Smith S, Hanson LM, Burkard MR, Cable L, Blake JF, Condroski KR, Brandhuber BJ, Andrews S, Rothenberg SM, Goto K
JCO Precis Oncol, 3:PO.19.00189, 11 Sep 2019
Cited by: 14 articles | PMID: 32923848 | PMCID: PMC7446343
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, [...] Drilon A
Ann Oncol, 29(8):1869-1876, 01 Aug 2018
Cited by: 198 articles | PMID: 29912274 | PMCID: PMC6096733
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, Smith S, Lauriault V, Kolakowski GR, Brandhuber BJ, Larsen PD, Bouhana KS, Winski SL, Hamor R, Wu WI, Parker A, Morales TH, Sullivan FX, DeWolf WE, [...] Hyman DM
Cancer Discov, 7(9):963-972, 03 Jun 2017
Cited by: 188 articles | PMID: 28578312 | PMCID: PMC5581710
Add to export list Free full text in Europe PMC
Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.
Rothenberg SM, Daniels GH, Wirth LJ
Clin Cancer Res, 21(24):5640-5641, 01 Dec 2015
Cited by: 23 articles | PMID: 26672087
Add to export list
Brain tumor cells in circulation are enriched for mesenchymal gene expression.
Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA
Cancer Discov, 4(11):1299-1309, 19 Aug 2014
Cited by: 158 articles | PMID: 25139148 | PMCID: PMC4221467
Add to export list Free full text in Europe PMC
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.
Rothenberg SM, Concannon K, Cullen S, Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA, Maheswaran S, Haber DA
Elife, 4, 16 Feb 2015
Cited by: 24 articles | PMID: 25686219 | PMCID: PMC4384750
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ
Clin Cancer Res, 21(5):1028-1035, 30 Dec 2014
Cited by: 160 articles | PMID: 25549723
Add to export list
Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.
McBride SM, Rothenberg SM, Faquin WC, Chan AW, Clark JR, Ellisen LW, Wirth LJ
Head Neck, 36(8):1181-1188, 10 Mar 2014
Cited by: 12 articles | PMID: 23852799 | PMCID: PMC4096067
Add to export list Free full text in Europe PMC
FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma.
Ramsey MR, Wilson C, Ory B, Rothenberg SM, Faquin W, Mills AA, Ellisen LW
J Clin Invest, 123(8):3525-3538, 08 Jul 2013
Cited by: 69 articles | PMID: 23867503 | PMCID: PMC3726171
Add to export list Free full text in Europe PMC
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA
Sci Transl Med, 5(196):196ra98, 01 Jul 2013
Cited by: 90 articles | PMID: 23903755 | PMCID: PMC3867020
Add to export list Free full text in Europe PMC
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.
Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR
Clin Cancer Res, 19(11):3088-3094, 03 Apr 2013
Cited by: 51 articles | PMID: 23553848 | PMCID: PMC3684567
Add to export list Free full text in Europe PMC

1-25 of 37 results

1 2

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion-Positive Breast Cancer.

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations.

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma.

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.

A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma.

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases.

Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer.

Selective RET kinase inhibition for patients with RET-altered cancers.

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.

Brain tumor cells in circulation are enriched for mesenchymal gene expression.

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.

Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.

FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma.

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.

Partnerships & funding